PT3134127T - Conjugados de anticorpo-fármaco com alta carga de fármaco - Google Patents
Conjugados de anticorpo-fármaco com alta carga de fármacoInfo
- Publication number
- PT3134127T PT3134127T PT157292244T PT15729224T PT3134127T PT 3134127 T PT3134127 T PT 3134127T PT 157292244 T PT157292244 T PT 157292244T PT 15729224 T PT15729224 T PT 15729224T PT 3134127 T PT3134127 T PT 3134127T
- Authority
- PT
- Portugal
- Prior art keywords
- drug
- antibody
- loading
- conjugates
- drug conjugates
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title 1
- 229940049595 antibody-drug conjugate Drugs 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461984645P | 2014-04-25 | 2014-04-25 | |
US201462028731P | 2014-07-24 | 2014-07-24 | |
US201562103999P | 2015-01-15 | 2015-01-15 | |
US201562147293P | 2015-04-14 | 2015-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3134127T true PT3134127T (pt) | 2020-04-09 |
Family
ID=53398151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT157292244T PT3134127T (pt) | 2014-04-25 | 2015-04-21 | Conjugados de anticorpo-fármaco com alta carga de fármaco |
Country Status (18)
Country | Link |
---|---|
US (1) | US11602525B2 (pt) |
EP (1) | EP3134127B1 (pt) |
JP (2) | JP6837273B2 (pt) |
KR (3) | KR20190072663A (pt) |
CN (1) | CN106456798B (pt) |
AU (1) | AU2015249452B2 (pt) |
BR (1) | BR112016024370A2 (pt) |
CA (1) | CA2946488C (pt) |
DK (1) | DK3134127T3 (pt) |
ES (1) | ES2783376T3 (pt) |
HU (1) | HUE049622T2 (pt) |
IL (1) | IL248221B (pt) |
MX (1) | MX2016013970A (pt) |
PL (1) | PL3134127T3 (pt) |
PT (1) | PT3134127T (pt) |
RU (1) | RU2674979C2 (pt) |
SI (1) | SI3134127T1 (pt) |
WO (1) | WO2015162563A1 (pt) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2914093T3 (es) * | 2014-06-12 | 2022-06-07 | Cspc Megalith Biopharmaceutical Co Ltd | Conjugados homogéneos de anticuerpo y fármaco mediante métodos enzimáticos |
AU2015282627B2 (en) | 2014-06-30 | 2020-04-02 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
PL3185908T3 (pl) * | 2014-08-28 | 2020-09-07 | Pfizer Inc. | Łączniki modulujące stabilność do stosowania z koniugatami przeciwciało-lek |
US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
WO2017096311A1 (en) | 2015-12-04 | 2017-06-08 | Seattle Genetics, Inc. | Conjugates of quaternized tubulysin compounds |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
MA44074A (fr) * | 2015-12-18 | 2018-10-24 | Eisai R&D Man Co Ltd | Immunoglobulines conjuguées à la lysine c-terminale |
CN105622924B (zh) * | 2016-02-03 | 2017-11-24 | 华东师范大学 | 一种组织蛋白酶b可裂解的嵌段聚合物及其制备方法和应用 |
US11786603B2 (en) | 2016-02-26 | 2023-10-17 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
WO2017151892A2 (en) * | 2016-03-02 | 2017-09-08 | Waters Technologies Corporation | Identification and quantification of conjugated peptides in antibody drug conjugates by mass spectrometry |
AU2017235571B2 (en) | 2016-03-18 | 2024-05-16 | Georgetown University | Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties |
US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
CN109311949B (zh) | 2016-05-11 | 2022-09-16 | 思拓凡生物工艺研发有限公司 | 储存分离基质的方法 |
US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
ES2909833T3 (es) | 2016-05-11 | 2022-05-10 | Cytiva Bioprocess R & D Ab | Método de limpieza y/o desinfección de una matriz de separación |
ES2874974T3 (es) | 2016-05-11 | 2021-11-05 | Cytiva Bioprocess R & D Ab | Matriz de separación |
US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
JP7041077B2 (ja) * | 2016-06-10 | 2022-03-23 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | リジン結合体化免疫グロブリン |
EP3272864A1 (en) * | 2016-07-20 | 2018-01-24 | Paul Scherrer Institut | Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation |
JP2018058822A (ja) | 2016-08-03 | 2018-04-12 | ファイザー・インク | ヘテロアリールスルホンをベースとするコンジュゲーションハンドル、これらの調製のための方法、および抗体薬物コンジュゲートの合成におけるこれらの使用 |
SG11201903400WA (en) * | 2016-10-17 | 2019-05-30 | Pfizer | Anti-edb antibodies and antibody-drug conjugates |
CN106589126A (zh) * | 2016-12-07 | 2017-04-26 | 中国药科大学 | 一种抗人cd24抗体突变体的设计及其应用 |
CA3052539C (en) * | 2017-02-08 | 2022-08-30 | Pfizer Inc. | Large scale production process for capped and un-capped antibody cysteines and their use in therapeutic protein conjugation |
KR102612882B1 (ko) | 2017-05-05 | 2023-12-11 | 센터 포 프로브 디벨롭먼트 앤드 커머셜리제이션 | 이관능성 킬레이트 및 그의 용도의 약동학적 증진 |
US10093741B1 (en) * | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
IL313115A (en) | 2017-05-05 | 2024-07-01 | Centre For Probe Dev And Commercialization | R1–IGF monoclonal antibodies and their use |
US11939385B2 (en) | 2017-05-16 | 2024-03-26 | ALX Oncology Inc. | Activatable antibodies and methods of use thereof |
CA3095067A1 (en) * | 2017-06-19 | 2018-12-27 | Sichuan Baili Pharm Co. Ltd | An antibody-drug conjugate having an acidic self-stabilization junction |
EP3679064A4 (en) | 2017-09-07 | 2021-06-02 | Cue Biopharma, Inc. | T-CELL-MODULATING MULTIMERAL POLYPEPTIDE WITH CONJUGATION SITES AND METHOD FOR USING THEREOF |
AU2018337671B2 (en) * | 2017-09-19 | 2021-03-04 | Paul Scherrer Institut | Transglutaminase conjugation method and linker |
US20200216463A1 (en) | 2017-09-20 | 2020-07-09 | Ph Pharma Co., Ltd. | Thailanstatin analogs |
SG11202003246WA (en) | 2017-10-27 | 2020-05-28 | Pfizer | Antibodies and antibody-drug conjugates specific for cd123 and uses thereof |
SG11202003995PA (en) * | 2017-11-14 | 2020-05-28 | Debiopharm Res & Manufacturing S A | Ligand-drug-conjugates as substrates for selective cleavage by the exopeptidase activity of cathepsin b |
US20220119545A1 (en) * | 2018-11-09 | 2022-04-21 | Beth Israel Deaconess Medical Center | Cdcp1-targeted therapies |
US11446401B2 (en) * | 2018-12-03 | 2022-09-20 | Fusion Pharmaceuticals Inc. | Actinium-225 and checkpoint inhibitor combination therapy |
EP3941526A1 (en) * | 2019-03-19 | 2022-01-26 | Paul Scherrer Institut | Transglutaminase conjugation method with a glycine based linker |
BR112022020332A2 (pt) * | 2020-04-10 | 2022-12-13 | Seagen Inc | Composto conjugado anticorpo-droga, composição, método de tratamento de câncer e de um distúrbio autoimune |
WO2024017923A1 (en) | 2022-07-20 | 2024-01-25 | F. Hoffmann-La Roche Ag | Linkers for site-specific antibody conjugation |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
WO1996006181A1 (fr) | 1994-08-23 | 1996-02-29 | Drug Delivery System Institute, Ltd. | Procede de modification de proteine |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
AU736549B2 (en) | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
US6919076B1 (en) | 1998-01-20 | 2005-07-19 | Pericor Science, Inc. | Conjugates of agents and transglutaminase substrate linking molecules |
CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
JP2003527561A (ja) | 1999-01-22 | 2003-09-16 | スミスクライン・ビーチャム・コーポレイション | 蛋白の部位特異的標識化方法およびそのための使用 |
WO2004042068A2 (en) | 2002-10-31 | 2004-05-21 | Northwestern University | Injectable and bioadhesive polymeric hydrogels as well as related methods of enzymatic preparation |
KR20060032140A (ko) | 2003-05-30 | 2006-04-14 | 센토코 인코포레이티드 | 트랜스글루타미나아제를 이용한 신규 에리트로포이에틴접합체의 형성 |
WO2004106939A2 (en) | 2003-06-03 | 2004-12-09 | Paul Scherrer Institut | Method for the linkage of bifunctional chelating agents and (radioactive) transition metal complexes to proteins and peptides |
EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
US20060019258A1 (en) | 2004-07-20 | 2006-01-26 | Illumina, Inc. | Methods and compositions for detection of small interfering RNA and micro-RNA |
ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
CA2623652C (en) | 2005-09-26 | 2013-11-26 | Medarex, Inc. | Antibody-drug conjugates and methods of use |
EP2076557A4 (en) | 2006-08-11 | 2012-08-29 | Starpharma Pty Ltd | POLYLYSINE DENDRIMER CONTRAST AGENT |
US20090181037A1 (en) | 2007-11-02 | 2009-07-16 | George Heavner | Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses |
JPWO2010002042A1 (ja) | 2008-07-04 | 2011-12-22 | 国立大学法人九州大学 | タンパク質ラベル化用酵素基質 |
WO2010011096A2 (en) | 2008-07-23 | 2010-01-28 | Hanmi Pharmaceutical Co., Ltd. | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
WO2010045270A2 (en) | 2008-10-13 | 2010-04-22 | San Diego State University Research Foundation | Compositions for labeling and identifying autophagosomes and methods for making and using them |
ES2550384T3 (es) | 2008-12-18 | 2015-11-06 | Dana-Farber Cancer Institute, Inc. | NKG2D-Fc para la inmunoterapia |
HUE036233T2 (hu) | 2009-12-06 | 2018-06-28 | Bioverativ Therapeutics Inc | VIII-FC Faktor kimérás és hibrid polipeptidek, és ezek használati módszerei |
JP5638628B2 (ja) | 2010-01-19 | 2014-12-10 | ハンミ サイエンス カンパニー リミテッドHanmi Scienceco.,Ltd. | 持続型エリスロポエチン結合体の液剤 |
RU2519031C1 (ru) | 2010-01-19 | 2014-06-10 | Ханми Сайенс Ко., Лтд. | Жидкие препаративные формы для длительно действующего конъюгата g-csf |
AR081755A1 (es) | 2010-04-02 | 2012-10-17 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo |
EP2635310A2 (en) * | 2010-11-05 | 2013-09-11 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
CU23923B1 (es) * | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
JP5936702B2 (ja) * | 2011-11-11 | 2016-06-22 | ライナット ニューロサイエンス コーポレイション | Trop−2に対して特異的な抗体およびこれらの使用 |
PL2780039T3 (pl) | 2011-11-17 | 2018-03-30 | Pfizer Inc. | Cytotoksyczne peptydy i ich koniugaty przeciwciało lek |
US9717803B2 (en) | 2011-12-23 | 2017-08-01 | Innate Pharma | Enzymatic conjugation of polypeptides |
JP6744212B2 (ja) * | 2013-06-21 | 2020-08-19 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | ポリペプチドの酵素的結合 |
EP3027224B1 (en) * | 2013-07-31 | 2020-06-03 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates using transglutaminase |
-
2015
- 2015-04-21 RU RU2016139340A patent/RU2674979C2/ru active
- 2015-04-21 PL PL15729224T patent/PL3134127T3/pl unknown
- 2015-04-21 ES ES15729224T patent/ES2783376T3/es active Active
- 2015-04-21 WO PCT/IB2015/052918 patent/WO2015162563A1/en active Application Filing
- 2015-04-21 CA CA2946488A patent/CA2946488C/en active Active
- 2015-04-21 US US15/306,481 patent/US11602525B2/en active Active
- 2015-04-21 BR BR112016024370A patent/BR112016024370A2/pt active Search and Examination
- 2015-04-21 CN CN201580029420.5A patent/CN106456798B/zh active Active
- 2015-04-21 KR KR1020197016878A patent/KR20190072663A/ko active Application Filing
- 2015-04-21 EP EP15729224.4A patent/EP3134127B1/en active Active
- 2015-04-21 PT PT157292244T patent/PT3134127T/pt unknown
- 2015-04-21 MX MX2016013970A patent/MX2016013970A/es active IP Right Grant
- 2015-04-21 HU HUE15729224A patent/HUE049622T2/hu unknown
- 2015-04-21 SI SI201531157T patent/SI3134127T1/sl unknown
- 2015-04-21 KR KR1020167032502A patent/KR20160145790A/ko not_active Application Discontinuation
- 2015-04-21 DK DK15729224.4T patent/DK3134127T3/da active
- 2015-04-21 KR KR1020217036185A patent/KR102430829B1/ko active IP Right Grant
- 2015-04-21 AU AU2015249452A patent/AU2015249452B2/en active Active
- 2015-04-23 JP JP2015088055A patent/JP6837273B2/ja active Active
-
2016
- 2016-10-06 IL IL248221A patent/IL248221B/en unknown
-
2021
- 2021-02-09 JP JP2021019197A patent/JP7194207B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US11602525B2 (en) | 2023-03-14 |
JP2015209426A (ja) | 2015-11-24 |
RU2674979C2 (ru) | 2018-12-14 |
EP3134127A1 (en) | 2017-03-01 |
RU2016139340A3 (pt) | 2018-05-25 |
ES2783376T3 (es) | 2020-09-17 |
KR20160145790A (ko) | 2016-12-20 |
PL3134127T3 (pl) | 2020-07-27 |
CN106456798A (zh) | 2017-02-22 |
WO2015162563A1 (en) | 2015-10-29 |
SI3134127T1 (sl) | 2020-06-30 |
KR20210135364A (ko) | 2021-11-12 |
IL248221B (en) | 2022-03-01 |
HUE049622T2 (hu) | 2020-09-28 |
DK3134127T3 (da) | 2020-03-16 |
AU2015249452A1 (en) | 2016-10-27 |
CN106456798B (zh) | 2021-02-12 |
AU2015249452B2 (en) | 2017-10-26 |
IL248221A0 (en) | 2016-11-30 |
JP2021091692A (ja) | 2021-06-17 |
US20170043033A1 (en) | 2017-02-16 |
KR102430829B1 (ko) | 2022-08-09 |
JP6837273B2 (ja) | 2021-03-03 |
EP3134127B1 (en) | 2020-02-26 |
CA2946488A1 (en) | 2015-10-29 |
CA2946488C (en) | 2021-11-09 |
KR20190072663A (ko) | 2019-06-25 |
MX2016013970A (es) | 2017-04-06 |
RU2016139340A (ru) | 2018-05-25 |
BR112016024370A2 (pt) | 2017-10-10 |
JP7194207B2 (ja) | 2022-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL248221B (en) | Antibody-drug conjugates with high drug loading | |
IL290116A (en) | Hydrophilic antibody-drug conjugates | |
ZA201607385B (en) | Anti-ptk7 antibody-drug conjugates | |
ZA201700306B (en) | Her2 antibody-drug conjugates | |
IL252015A0 (en) | Antibody drug conjugates | |
IL250189A0 (en) | Anti–cdh6 antibody drug conjugates | |
IL250319B (en) | Stability-promoting linkers for use in drug-antibody conjugates | |
PL3148591T3 (pl) | Koniugaty nanocząstka-lek | |
GB201614443D0 (en) | Targeted drug conjugates | |
GB201504694D0 (en) | Covalent conjugates | |
GB201418984D0 (en) | Novel drug conjugates | |
GB201419996D0 (en) | Targeted drug conjugates | |
GB201407533D0 (en) | Targeted drug conjugates | |
GB201419994D0 (en) | Small molecule drug conjugates | |
GB201401818D0 (en) | Targeted drug conjugates | |
GB201407530D0 (en) | Small molecule drug conjugates | |
GB201408176D0 (en) | Ligand drug conjugates | |
GB201401819D0 (en) | Small molecule drug conjugates |